Temozolomide in pediatric low-grade glioma
Data(s) |
01/11/2007
|
---|---|
Resumo |
BACKGROUND: We describe a retrospective series of children with low-grade glioma who received temozolomide. PROCEDURE: Eligible patients had had a diagnosis of low-grade glioma with or without histological confirmation. Temozolomide was administered at a dose of 200 mg/m(2) daily for 5 days, in a 4-week cycle. Therapy was stopped on completion of the targeted 12 cycles of chemotherapy or on evidence of tumor progression. RESULTS: Thirteen eligible patients were identified, eight male and five female. Median age at diagnosis was 5.5 years (range 2.6-15.0 years) and at commencement of temozolomide treatment was 9.0 years (range 3.8-15.2 years). Nine patients had a histological diagnosis of pilocytic astrocytoma. Twelve patients had received carboplatin prior to temozolomide, including three in combination with vincristine. A total of 111 cycles of therapy have been administered. Hematological toxicity and nausea were the most common adverse effects. Median time to progression was 6.7 months (range 1.5-41.8 months). Event-free survival rate at 3 years was 57%. Twelve of 13 patients remain alive at the time of report. Eleven have stable disease (SD). CONCLUSION: Temozolomide appears to be active in pediatric low-grade glioma, with the advantage of oral administration and excellent tolerability. |
Identificador | |
Idioma(s) |
eng |
Publicador |
Wiley |
Relação |
http://dro.deakin.edu.au/eserv/DU:30070891/ashley-temozolomidein-2007.pdf http://www.dx.doi.org/10.1002/pbc.21270 |
Direitos |
2007, Wiley |
Palavras-Chave | #Adolescent #Antineoplastic Combined Chemotherapy Protocols #Astrocytoma #Brain Neoplasms #Carboplatin #Child #Child, Preschool #Dacarbazine #Disease-Free Survival #Female #Hematologic Diseases #Humans #Male #Nausea #Retrospective Studies #Spinal Cord Neoplasms #Survival Rate #Vincristine #Science & Technology #Life Sciences & Biomedicine #Oncology #Hematology #Pediatrics #low-grade glioma #temozolomide #PHASE-II TRIAL #OPTIC PATHWAY TUMORS #RECURRENT OLIGODENDROGLIOMA #VINCRISTINE CHEMOTHERAPY #CHILDREN #RADIOTHERAPY #CHILDHOOD #GLIOBLASTOMA |
Tipo |
Journal Article |